MedTrace Logo

Evaluation of the Safety of Relaxin in Preeclampsia

NCT00333307 · Status: SUSPENDED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2010-03-16

No results posted yet for this study

Summary

The purpose of this study is to determine whether different doses of recombinant human relaxin is safe when given to women with severe preeclampsia

Conditions

  • Pre-Eclampsia

Interventions

DRUG

recombinant human relaxin

Sponsors & Collaborators

  • Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies

    lead INDUSTRY

Principal Investigators

  • Sam Teichman, MD · Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00333307 on ClinicalTrials.gov